| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458143 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(5 years from now) | |
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(5 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
Qelbree is owned by Supernus Pharms.
Qelbree contains Viloxazine Hydrochloride.
Qelbree has a total of 5 drug patents out of which 0 drug patents have expired.
Qelbree was authorised for market use on 02 April, 2021.
Qelbree is available in capsule, extended release;oral dosage forms.
Qelbree can be used as for the treatment of attention deficit hyperactivity disorder (adhd).
Drug patent challenges can be filed against Qelbree from 02 April, 2025.
The generics of Qelbree are possible to be released after 07 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
| New Patient Population(NPP) | Apr 29, 2025 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QELBREE family patents
